Over the past decade, input–output structural decomposition analysis (SDA) has developed into a major analytical tool. We review the development of SDA and its relationship to other methodologies. We present the fundamental principles of alternative approaches to deriving SDA estimating equations and explore the various decompositions of changes in IO tables. We also identify several complications and unresolved issues. Most importantly, we find that a rigorous grounding in economic theory is lacking for SDA, but we are able to offer some suggestions as to how it might be established. 相似文献
Summary The development of tourism in China over the last two decades is reviewed. It is argued that the success of the economic reforms in China which has resulted in fast economic growth has also been the main cause of rapid tourism growth in China. Forecasts of international tourist arrivals by source country market and destination region within China are generated over the period 2001-05. An integrative approach is used which combines both time-series and econometric methodologies, termed structural integrated time-series econometric analysis (SITEA). 相似文献
This study integrated the theoretical perspective of social capital into community-based ecotourism (CBET). Two destinations were selected to test the conceptual model to see whether social capital improves cooperation between community residents and the coordination of CBET development, and whether its role is persuasive and encourages residents' pro-environmental behaviors. The sample consisted of 420 residents living in two typical ecotourism destinations in China. Findings from a two-stage structural equation model analysis show that economic benefits have a direct impact on residents' pro-environmental behaviors; and the cognitive, rather than structural social capital has a partially mediating effects on this relationship. These findings indicate that a high level of social capital, particularly the cognitive variant, is instrumental in encouraging residents' pro-environmental behaviors. 相似文献
Background: Overactive bladder (OAB) is a common condition that has a significant impact on patients’ health-related quality-of-life and is associated with a substantial economic burden to healthcare systems. OnabotulinumtoxinA has a well-established efficacy and safety profile as a treatment for OAB; however, the economic impact of using onabotulinumtoxinA has not been well described.
Methods: An economic model was developed to assess the budget impact associated with OAB treatment in France, Germany, Italy, Spain and the UK, using onabotulinumtoxinA alongside best supportive care (BSC)—comprising incontinence pads and/or anticholinergic use and/or clean intermittent catheterisation (CIC)—vs BSC alone. The model time horizon spanned 5 years, and included direct costs associated with treatment, BSC, and adverse events.
Results: Per 100,000 patients in each country, the use of onabotulinumtoxinA resulted in estimated cost savings of €97,200 (Italy), €71,580 (Spain), and €19,710 (UK), and cost increases of €23,840 in France and €284,760 in Germany, largely due to day-case and inpatient administration, respectively. Projecting these results to the population of individuals aged 18 years and above gave national budget saving estimates of €9,924,790, €27,458,290, and €48,270,760, for the UK, Spain, and Italy, respectively, compared to cost increases of €12,160,020 and €196,086,530 for France and Germany, respectively. Anticholinergic treatment and incontinence pads were the largest contributors to overall spending on OAB management when onabotulinumtoxinA use was not increased, and remained so in four of five scenarios where onabotulinumtoxinA use was increased. This decreased resource use was equivalent to cost offsets ranging from €106,110 to €176,600 per 100,000 population.
Conclusions: In three of five countries investigated, the use of onabotulinumtoxinA, in addition to BSC, was shown to result in healthcare budget cost savings over 5 years. Scenario analyses showed increased costs in Germany and France were largely attributable to the treatment setting rather than onabotulinumtoxinA acquisition costs. 相似文献